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A R E RELATED TO TUMOR PROGRESSION IN SITU BUT NOT TO 
METASTATIC CAPACITY OF CELL LINES IN NUDE MICE
Erik HJ. Danen1, Kees F.J, Jansen, Annemieke A. Van Kraats, Ine M.HA. Cornelissen,
Dirk J. Ruiter and Goos N.P. Van Muijen
Department o f  Pathology, University Hospital Nijmegen, Nijmegen, The Netherlands.
We investigated the expression of <vintegrins »n different 
stages of human cutaneous melanocytic tumor progression. We 
observed that was the Oy-integrin expressed in all common 
nevocelluiar nevi, in 78% of dysplastic nevi, in 63% of early 
primary melanomas, in 43% of advanced primary melanomasy 
and in 33% of melanoma métastasés. Hence, loss of 0 ^ 5  
expression was related to melanocytic tumor progression. In 
line with earlier reports, ocyp3 was exclusively detected in 
advanced primary melanomas and métastasés (24% and 50% 
respectively). Staining with anti-oty monoclonal antibodies (MAbs) 
in lesions where both 0 ^ 3  and a^ Ps were absent showed that 
alternative «vintegrins were expressed in advanced primary 
melanomas and métastasés. By FACS analysis, we determined 
expression of and 0 ^ 3  in 4 human melanoma cell lines with 
different metastatic capacities after s.c. inoculation into nude 
mice. One of the non-metastatic and both highly metastatic cell 
lines expressed c^ps at their surface. Surprisingly, c^ p^  was 
detected exclusively in the non-metastatic cell lines. Absence of 
0 ^ 3  in the highly metastatic cell lines was confirmed by lack of 
immunoprécipitation from 35S-methionine-labeled cells and by 
absence of immunohistochemical staining on primary and meta­
static xenograft lesions. Our findings indicate that c^ps expres­
sion is often lost in advanced stages of melanocytic tumor 
progression in situ, while 0 ^ 3  is acquired, but that a decrease in 
OvPs and an increase in Oyp3 expression are not necessarily 
related to the metastatic behavior of human melanoma cells in 
nude mice.
© 1995 Wiley-Liss, Inc.
The extracellular matrix (ECM) regulates a number of 
cellular processes, while integrins link the ECM to structural 
elements in the cell and play a role as signalling receptors 
(Hynes, 1992). Therefore, it is likely that integrins can mediate 
ECM control of cell growth, migration and invasion. These 
processes play an important role in tumorigenicity and metas­
tasis formation and integrins have indeed been shown to be 
involved in both occurrences (Juliano and Varner, 1993).
In human melanoma, integrins have been shown to be 
involved in tumor growth and metastatic spread (Mortarini 
and Anichini, 1993). For melanocytic tumor progression in situ, 
changes in the expression of several integrins have been 
reported, including acquired expression of avp3 in the vertical 
growth phase of primary melanomas and in métastasés (Al- 
belda et al, 1990). The av-subunit of this integrin, however, can 
be associated with several different p-subunits in melanoma 
cells in vitro (Marshall et ai, 1991) and is expressed in all stages 
of melanocytic tumor progression in situ (Danen et ai, 1994). 
In this study we have investigated expression of av-integrins in 
cutaneous melanocytic lesions and in a panel of human 
melanoma cell lines with different metastatic capacities in 
nude mice.
M ATERIAL AND METHODS
Lesions
Specimens were obtained from patients at the University 
Hospital, Nijmegen, The Netherlands and at the University 
Hospital, Würzburg, Germany. Based on histopathologic exami­
nation of paraffin sections, lesions were divided into 5 classes: 
common nevocelluiar nevus (NN) (n = 19), dysplastic (atypi­
cal) nevus (DN; De Wit et al, 1993) (n = 9), early primary
melanoma (tumor thickness <1.5 mm; ePM) (n = 8), ad­
vanced primary melanoma (tumor thickness >1.5 mm; aPM) 
(n = 21) and melanoma metastasis (MM) (n = 24). Represen­
tative samples were snap-frozen in liquid nitrogen and stored 
at ~80°C until sectioning.
Cell lines and culture conditions
The melanoma cell lines used included: IF6 (Van Muijen et 
a l, 1991fl), 530 (Versteeg et al., 1988), BLM (Van Muijen et a l,  
1991«), MV3 (Van Muijen et a i , 1991Z?) and Mel57 (Van 
Muijen et a l, 1991a). All cell lines were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM; Flow, Irvine, UK) supple­
mented with 10% FCS, penicillin and streptomycin.
Monoclonal antibodies
The anti-integrin MAbs used were: 4B4 anti-pl (Morimoto 
et a l, 1985) (Coulter, Hialeah, FL), LM142 anti-av and LM609 
anti-avp3 (Cheresh and Spiro, 1987) (kind gifts from Dr. D. 
Cheresh, La Jolla, CA), 13C2 anti-c*v and 23C6 anti-avp3 
(Davies et al,, 1989) (kind gifts from Dr. M. Horton, London, 
UK), and P1F6 anti-av3s (Wayner et a l 1991) (Telios, San 
Diego, CA). In FACS analyses WT31 anti-CD3 MAbs (Tax e t  
a l, 1983) (kind gift from Dr. W. Tax, Nijmegen, The Nether­
lands) were used as a negative control. NKI-beteb anti-gplOO 
MAbs (Adema et a l, 1993) (kind gift from Dr. C. Figdor, 
Nijmegen, The Netherlands) were used to identify melanocytic 
cells in human lesions.
Immunohistochemistiy
Identical procedures were used for immunohistochemistry 
of frozen sections of human melanocytic lesions and melanoma 
cell line xenograft lesions. Frozen sections of 4 jxm were fixed 
in acetone for 10 min and incubated at room temperature with 
MAbs for 1 hr. After washing with PBS, bound MAbs were 
visualized by means of the peroxidase-based Vectastain elite 
ABC kit (Vector, Burlingame, CA) with 3-amino-9-ethyIcarba- 
zole as substrate. After counterstainingwith Mayer’s hematoxy­
lin, sections were mounted with Kaiser’s glycerin/gelatin 
(Merck, Darmstadt, Germany).
Melanocytic cells were identified in H. and E.-stained 
sections and by staining with NKI-beteb MAbs. The percent­
age of stained melanocytic cells was estimated as 0, 1-25%, 
26-50%, 51-75%, or 76-100%. Slides were read indepen­
dently by 2 observers. Discrepancies exceeding more than one 
percentage class were found in less than 10% of the cases. 
These cases were re-evaluated jointly until consensus was 
reached.
Logistic regression was used to determine a correlation 
between antigen expression and tumor progression.
*To whom correspondence and reprint requests should be sent, at 
the Department of Pathology, University Hospital Nijmegen, P.O. Box 
9101,6500 HB Nijmegen, The Netherlands. Fax: 31 80 540520.
Received: January 4,1995.
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Flow cytometry
Cells were harvested by short trypsinization of subconfluent 
monolayers and suspended in DMEM/10% FCS. After wash­
ing with PBS containing 0.5% BSA and 0.02% azide, they were 
incubated with MAbs in PBS/BSA/azide for 30 min at 4°C. 
After washing with PBS/BSA/azide, the cells were incubated 
with fluorescein-isothiocyanate (FITC)-conjugated F(ab')2 
fragments of rabbit anti-mouse Ig antibodies (Dako, Glostrup, 
Denmark). Analyses were performed with an Epics Elite flow 
cytometer (Coulter, Mijdrecht, The Netherlands).
Immun oprecipitation
Immunoprécipitations were performed as described earlier 
(Danen et al., 1993). Briefly, ceils were labeled overnight with 
0.3 mCi 35S-methionine (Amersham, Houten, The Nether­
lands), washed and lysed with 0.5% NP40 lysis buffer. Glycopro­
teins were isolated from NP40-solubilized cell extracts by 
adsorption to concanavalin A (Con A) Sepharose (Pharmacia, 
Uppsala, Sweden). To compare the amount of glycoproteins in 
the different cell lines, equal numbers of counts of the 
Con A-bound fractions were used for immunoprécipitation. 
MAbs, rabbit anti-mouse Ig (Dako, Glostrup, Denmark) and 
ProtA beads (Pharmacia) were subsequently added and the 
volume was adjusted to 1 mí with 0.5% NP40. Samples were 
tumbled overnight at 4°C and the beads washed 3 times with 
0.5% NP40 and 5 times with 0.5% NP40/0.1% SDS. Finally,
the beads were resuspended in sample buffer containing 
2-mercaptoethanoI, then boiled and run on SDS-PAGE.
avb5 avb3
RESULTS
Expression o f  avp5 in situ
In order to investigate which av-integrins are expressed in 
benign melanocytic lesions and to see whether other av- 
integrins besides avp3 are expressed in malignant melanoma, 
we stained a series of NN, DN, ePM, aPM and MM with P1F6 
anti-avP5 MAbs. Besides staining of fibroblast-like cells in 
stroma of all lesions, staining of melanocytic cells was found in 
100% of NN (19/19), in 78% of DN (7/9), in 63% of ePM 
(5/8), in 43% of aPM (9/21) and in 33% of MM (8/24) (Figs. 1, 
2). Hence, loss of expression of avPs was related to tumor 
progression (CHI2 trend 1 d.f. = 16.3; p  =  0.0001). In the 
esions that were positive for avp5> a variable heterogeneous 
staining pattern was observed with 25-100% positive melano­
cytic cells.
Expression o f  other av-integtins in situ
In contrast to avP5, staining for avp3 was absent in NN, DN
and ePM, whereas 24% of aPM (5/21) and 50% of MM
(12/24) were positive, indicating that avp3 emerged in aPM
and MM (CHI2 trend 1 d.f. = 14.4; p  = 0.0001) (Figs. 1, 2).
Incubation with 23C6 or LM609 anti-avp3 MAbs gave similar
results. In all lesions, staining of blood vessels was observed. In
2 DN, 4 ePM, 10 aPM and 6 MM neither nor avp5 could be
detected and we incubated these lesions with 13C2 and LM142
anti-otv MAbs. Staining was negative for the 2 DN and 4 ePM
lesions, whereas 5/10 aPM and 5/6 MM lesions were positive,
indicating that other av-integrins were expressed (not shown).
Incubation with 4B4 anti-pi MAbs resulted in staining of all
melanocytic ceils in all lesions (not shown), indicating that avPi
may possibly be the av-integrin expressed in aPM and MM 
lesions.
Expression o f  avps and in human melanoma cell lines
We next examined whether decreased expression of avp5 
and increased expression of avp3 also correlated with the 
metastatic potential of cultured human melanoma cells. For 
this purpose we used a panel of 4 human melanoma cell lines. 
After s.c. inoculation into nude mice, all 4 cell lines were seen
ePM
aPM
100 80 60 40 20 0 20 40 60 80 100
% positive lesions
F igure  1 - Expression of avps and avp3 in different stages of 
human melanocytic tumor progression. Nineteen NN, 9 DN, 8 
ePM, 21 aPM and 24 MM were stained with P1F6 anti-avp5 and 
23C6 and LM609 anti-avp3 MAbs. Percentages of lesions in which 
positive melanocytic cells were observed are indicated. In the 
esions that were positive, 25-100% of melanocytic cells stained.
to be tumorigenic but IF6 and 530 gave rise to metastases in 
only a very low percentage of mice or in none at all, whereas 
BLM and MV3 very frequently metastasized (Van Muijen et 
aL, 1991«, b ). FACS analysis showed that comparable levels of 
avp5 were expressed on IF6, BLM and MV3 whereas no avP:> 
could be detected on 530 cells. (Fig. 3a). Surprisingly, no avp3 
was detected on the highly metastatic cell lines BLM and MV3, 
whereas the non-metastatic cell lines IF6 and 530 expressed 
ctvp3 at their surface (Fig. 3b). Hence, the relation of decreased 
avp5 and increased avp3 expression with melanocytic tumor 
progression in situ was not paralleled by a relation with the 
metastatic capacity of human melanoma cells in nude mice.
Biosynthesis o f  in human m elanom a cell lines
In order to investigate whether the absence of a vp3 from the 
surface of BLM and MV3 cells was reflected by a lack of 
biosynthesis of avP3 in these cells, immunoprecipitations were 
performed on 35S-methionine-labeIed cells. Consistent with 
the surface expression data, synthesis of avp3 was extremely 
low for the highly metastatic BLM and MV3 cells. For the 
non-metastatic IF6 and 530 cells, a clear 125-kDa band 
corresponding to av and a 105-kDa band corresponding to p3 
were detected, whereas these bands were barely visible for 
BLM and MV3 cells (Fig. 4). The 90-kDa and 150-kDa bands 
were non-specific since they could be detected even after 
incubation with normal mouse serum (NMS).
Expression o f  avft in xenog}‘aft lesions
In order to exclude the possibility that absence of avp3 in the 
highly metastatic cell lines in vitro was due to culture condi­
tions, we stained xenograft lesions of these cell lines with 
anti-avp3 MAbs. No avp3 was detected in primary tumors or 
metastases of BLM and MV3 cells, whereas control anti-Pi 
MAbs stained all tumor cells (Fig. 5). For IF6 and 530 cells 
that expressed avp3 in vitro, we could not detect avp3 in 
xenograft lesions (not shown), suggesting that the level of 
expression was too low for immunohistochemical detection or, 
alternatively, that culturing the cells might influence the 
expression of avp3. Therefore, we stained s.c. xenograft lesions 
of Mel57 melanoma cells that strongly express avp3 in vitro (our 
unpublished data), as a positive control. As shown in Figure 5,
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F igure 2 -  Microphotographs of melanocytic lesions stained with anti-av-integrin MAbs. Melanocytic lesions were stained with 23C6 
and LM609 anti-avp3 or P1F6 anti-avp5 MAbs. Arrowheads indicate nevus (a-d) or melanoma (e-j) cells. (a,  b) NN negative for ayp3 (a) 
and positive for c^Ps (b). (c, d) DN negative for avp3 (c; arrow = positive blood-vessel) and positive for avps (d). (e, f) ePM negative for 
avp3 ((?; arrow = positive blood vessel) and positive for o¿vP5 (f). (g, h) aPM positive for OvP3 (g) and negative for avp5 (h) (s = stromal 
cells). (i,j)  MM positive for avp3 (i) and negative for avps (j) (s = stromal cells). Bars: 20 jxm.
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Figure 3 -  Surface expression of Ov-integrins on human mela­
noma cell lines, IF6 (thin line), 530 (thin dotted line), BLM (thick 
line) and MV3 (thick dotted line) were incubated with P1F6 
anti-ctvPs (a) or LM609 anti-o^fo MAbs (b) followed by FITC- 
labeled second antibodies. Fluorescence was measured on an 
Epics Elite flow cytometer. The vertical line indicates the gate set 
with control anti-CD3 MAbs. Results with 23C6 MAbs were 
identical to those with LM609.
Mel57 melanoma cells stained strongly with LM609 MAbs in 
xenograft lesions, Hencc, in line with the in vitro 
findings,primaty tumors and lung métastasés in nude mice of 
the highly metastatic human melanoma cell lines BLM and 
MV3 did not show <xvp3 expression.
DISCUSSION
Cutaneous melanoma is characterized by proliferative and 
invasive growth in the dermis and is often followed by 
widespread metastasis. Interactions of tumor cells with the 
ECM, which are mainly mediated by integrins (Hynes, 1992), 
are thought to play an important role in the malignant 
behavior of melanoma (Mortarini and Anichini, 1993) and 
other human tumors (Juliano and Varner, 1993). In the 
present study, we investigated the expression of cvintegrins in 
human melanocytic tumor progression in situ and in a panel of 
human melanoma cell lines with different metastatic capacities 
after s.c. inoculation into nude mice.
Acquired expression of av$3 in the vertical-growth phase of 
primary melanomas and in melanoma metastases has been 
reported (Albelda et al, 1990) whereas the cvsubunit is 
expressed in all stages of melanocytic tumor progression 
(Danen et al., 1994). In vitro, melanoma cells have been shown 
to express avp3, avfr (Marshall et al, 1991) and avp5 (Wayner et
F ig u r e  4 -  Biosynthesis of otvp3 in human melanoma cell lines. 
IF6, 530, BLM and MV3 were'metabolically labeled with 35S- 
methionine and lysed, then glycoproteins were isolated on Con A 
Sepharose, Equal numbers of Con A-bound counts were used for 
immunoprécipitation with 23C6 anti-avp3 MAbs or NMS as a 
negative control. Identical results were obtained with LM609 
MAbs.
al, 1991). In this study we have investigated which of the 
cvintegrins are expressed in situ in nevi and in primary 
melanomas and metastases. Our data concerning avPa expres­
sion confirm the findings from previous studies (Albelda e*al., 
1990) and show that avp3 emerges in aPM and MM. Regarding 
avp5, we find that expression is often lost with melanocytic 
tumor progression. Since no MAbs have yet been generated 
recognizing the avpt complex, we could not investigate expres­
sion of this integrin. For the lesions with avp3 and/or avp5 
expression we cannot exclude the possibility that other ov 
integrins are expressed as well. For those lesions in which 
neither cxvp3 nor avp5 was detected, we investigated whether 
alternative <vintegrins were expressed. The fact that alterna­
tive cvintegrins were not detected in DN or ePM, whereas a 
number of PM and MM did express other cvintegrins, 
suggests that additional cvintegrins may emerge in aPM and 
MM besides avp3. Thus, in NN, DN and ePM, avp.5 may be 
expressed, whereas in aPM and MM avp5, avp3 and/or other 
cvintegrins may be expressed. Since all lesions were pp 
positive, and since avp! can be expressed by melanoma cells in 
vitro (Marshall et al, 1991), avPi may be the alternative 
emerging cvintegrin.
The fact that avp5 expression is lost in most MM and that 
expression of avp3 emerges may have functional consequences 
for the melanoma cells. The ligand-binding specificity of avps 
seems to be restricted to vitronectin whereas avp3 recognizes 
multiple ligands including vitronectin and iibronectin (Smith et 
ai, 1990). In addition, avps and avp3 promote distinct cellular 
responses to vitronectin in vitro (Leavesey et al, 1992). We 
have recently shown that, for melanomas originating from the 
uvea, avp3 is absent in all primary lesions including those of the 
aggressive type, and that avps is the cvintegrin expressed (Ten 
Berge et al, 1993). This may indicate that the microenviron­
ment of the melanoma cells is important in determining which 
cvintegrins are expressed. The fact that a role in proliferation 
(Fehlding-Habermann el al, 1992) and invasion (Seftor et al, 
1992) of melanoma cells has been attributed to avp3 seems to 
be in line with the emergence of avp3 in aPM and friM. In our 
panel of human melanoma cell lines, IF6 and 530 express avp3 
in vitro but no <xvp3 can be detected in the primary xenograft
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F i g u r e  5 ~ Expression of avp3 in xenograft lesions. Frozen sections from MV3 s.c. tumor (a, b, cj, MV3 lung metastasis (d, e, f), and 
Mel57 s.c. tumor (g, //, i), were stained either in the absence of primary MAbs (a, d, g), with LM609 anti-avP3 (b} e, h) or with 4B4 anti-P! 
MAbs (c, ƒ  i). Results for BLM were identical to those shown for MV3. Bar: 20 jxm.
tumors, which grow slowly. On the other hand, BLM and MV3 
tumors lack a vp3 and grow rapidly. All 4 cell lines develop 
tumors upon s.c. inoculation into nude mice (Van Muijen et cil, 
1991a, b). This suggests that avP3 is not necessarily involved in 
melanoma tumor growth. Furthermore, the fact that, for the 
highly metastatic cell lines, avP3 expression is absent in vitro ,  in 
s.c. xenograft lesions and in lung metastases, suggests that they 
use alternative integrins for metastasizing in nude mice.
In conclusion, we show that avp5 is often lost in advanced 
stages of melanocytic tumor progression in situ while avp3 
emerges, but that decrease in avp5 and increase in avp3 are not
necessarily related to the metastatic potential of human 
melanoma cell lines in nude mice.
ACKNOWLEDGEMENTS
We thank Drs. D. Cheresh, C. Figdor, M. Horton and W. 
Tax for generously providing antibodies and Dr. E.-B. Brocker 
for kindly providing some of the specimens. W e are indebted 
to Dr. B. v a n ’t Hof-Grootenboer for statistical analyses. This 
work was supported by grant NUKC 91-09 from the Dutch 
Cancer Society.
496 DANEN ETAL
REFERENCES
A d h m a , G.J., D e Bo e r , A.J., V a n ’t  H u l l e n a a r , R ,  D e n ij n , Mm 
R u it e r , D.J., V o g e l , A.M. and F ig d o r , C.G., Melanocyte lineage 
specific antigens recognized by monoclonal antibodies NKI-beteb, 
HMB50, and HMB45 are encoded by a single cDNA. Amer. J. Pathol, 
143,1579-1585 (1993).
A lbeld a , S.M., M e t t e , S.A., E l d e r , D.E., St e w a r t , R., D a m ja n o v - 
ich , L., H e r l y n , M . and B u c k , C., Integrin distribution in malignant 
melanoma: association of the p3 subunit with tumor progression. 
Cancer Res., 50, 6757-6764 (1990).
C h e r e s h , D.A. and Sp ir o , R .C ., Biosynthetic and functional proper­
ties of an Arg-Gly-Asp-directed receptor involved in human mela­
noma cell attachment to vitronectin, fibrinogen, and von Willebrand 
factor. J. biol. C h e m 262,17703-17711 (1987).
D a n e n , E.H.J., T en B e r g e , P.J.M., V a n  M u ij e n , G.N.P., V a n ’t  
H o f -G r o o t e n b o e r , B., B r o c k e r , E.B. and R u it e r , D .J ., Emergence 
of as(3i fibronectin- and av03 vitronectin receptor during melanoma 
progression. Histopathology, 24,249-256 (1994).
D a n e n , E .H .J ., V a n  M u ije n , G.N.P., V a n  d e  W ie l -V a n  K e m e n a d e , 
P., J a n se n , C.F.J., R u it e r , D.J. and F ig d o r , C.G., Regulation of 
integrin-mediated adhesion to laminin and collagen in human melano­
cytes and in non-metastatic and highly metastatic human melanoma 
cells. Int. J. Cancer, 54,315-321 (1993).
D a v ies , J., W a r w ic k , J., T o t t y , N., P h il ip , R., H e l f r ic h , M. and 
H o r t o n , M., The osteoclast functional antigen, implicated in the 
regulation of bone resorption, is biochemically related to the vitronec­
tin receptor. J. Cell Biol, 109,1817-1826 (1989).
D e W it , P.E.J., V a n ’t  H o f -G r o o t e n b o e r , B., R u i t e r , D.J., B o n d i , 
R., Br o c k e r , E.B., C e s a r in i , J.P., H a s t r u p , N ., H o u J e n s e n , K., 
M a Ck ie , R .M ., S c h e f f e r , E., S u t e r , L. and U r s o , C ., Validity of the 
histopathological criteria used for diagnosing dysplastic naevi. Europ. 
J. Cancer, 29A, 831-839 (1993).
F el d in g -FIa b e r m a n n , B., M u e l l e r , B .M ., R o m e r d a h l , C, and 
C h e r e s h , D.A., Involvement of integrin a v gene expression in human 
melanoma tumorigenicity./. clin. Invest, 89,2018-2022 (1992).
H ynes , R.O., In teg rins: versatility , m o d u la tio n  a n d  signalling  in cell 
adhesion . Cell, 69,11-25 (1992).
J uljano , R.L. and V a r n e r , J .A ., Adhesion molecules in cancer: the 
role of integrins. Curr. Opin. Cell Biol., 5, 812-818 (1993).
L ea vesley , DJ., F e r g u s o n , G.D., W a y n e r , E.A. and C h e r e s h , 
D.A., Requirement of the integrin p3 subunit for carcinoma cell 
spreading or migration on vitronectin and fibrinogen. J. Cell Biol, 117, 
1101-1107(1992).
M arshall , J.F., N esbitt, S.A., H elfrich , M.H., H o r t o n , M .A ., 
Polakova , K. and H a r t , I.R., Integrin expression in human mela­
noma cell lines: heterogeneity of vitronectin receptor composition and 
function. Int. J. Cancer, 4 9 ,924-931  (1991).
M orimoto , C., Letvin , N.L., B o y d , A.W., H a g a n , M„ B r o w n , H.M., 
Kornacki, M.M. and Schlossman , S.F., The isolation and character­
ization of the human helper inducer T  cell subset. J. Immunol., 134,
3762-3769 (1985).
M ortarini, R. and A nichini, A ., From adhesion to signalling: roles of  
integrins in the biology of human melanoma. Melanoma Res., 3, 8 7 -9 7  
(1993).
Seftor , R.E.B., Seftor , H.A., G eh l sen , K.R., St e t l e r -St e v e n s o n , 
W .G., B row n , P.D., R uoslahti, E. and H e n d r ix , M J.C., Role o f the 
avp3 integrin in human melanoma cell invasion. Proc. nat. Acad. ScL 
(Wash.), 8 9 ,1557-1561 (1992).
Smith, J.W., V estal , D.J., Ir w in , S.V., B u r k e , T.A. and C h e r e sh , 
D.A., Purification and functional characterization of integrin avfi5; an 
adhesion receptor for vitronectin. J. biol. Chem,, 265, 11008-31013  
(1990).
Ta x , W.J.M., W illems, H.W., R eek ers , P.P.M., Ca p e l , PJ.A . and 
Koene , R.A.P., Polymorphism in mitogenic effect of IgG l monoclonal 
antibodies against T3 antigen on human T  cells. Nature (Lond.), 304, 
445-447  (1983).
T en B e r g e , P.J.M., D a n e n , E .H J., V an  M u ije n , G.N.P., Ja g e r , M.J. 
and R uiter , D.J., Integrin expression in uveal m elanom a differs from  
cutaneous m elanom a. Invest. Ophthalmol vis. Sci., 34, 3 6 3 5 -3 6 4 0  
(1993).
V an M uijen , G.N.P., Co rnelissen , L.M.H.A., Ja n s e n , C.F.J., F ig­
d o r , C.G., Jo h n so n , J.P., B ro c k er , E.B. and R u it e r , D.J., Antigen 
expression of metastasizing and non-metastasizing human melanoma 
cells xenografted into nude mice. Clin. exp. M e ta s t9 , 2 5 9 -2 7 2  (1991a ).
V an  M uijen , G.N.P., Ja n se n , C .F J., C o r n elissen , I.M.H.A., S m eets , 
D.F.C .M ., B eck , J.L.M. and R u it e r , D.J., Establishment and charac­
terization of a human melanoma cell line (M V 3) which is highly 
metastatic in nude mice. Int. J. Cancer; 48, 85—91 (1991/?).
V ersteeg , R„ N o o r d e r m e er , LA., K r u sse-W o lters , M., R u it e r , 
D J. and S c h r i e r ,  P.I., C-myc down-regulates class-I HLA expression 
in human melanomas. EMBOJ., 7 ,1 0 2 3 -1 0 2 9  (1988).
W a y n e r , E.A., O r l a n d o , R.A. and C h e r e sh , D.A., Integrins a vp3 
and avps contribute to cell attachment to vitronectin but differentia ly 
distribute on the cell surface./. Cell Biol, 113, 919-929  (1991).
